Related Experiment Videos
Itraconazole-enhanced vincristine neurotoxicity in a child with acute lymphoblastic leukemia
1Department of Pediatric Hematology/Oncology, Children's Hospital Oakland, Oakland, California, USA.
Insights
Itraconazole can dangerously enhance vincristine neurotoxicity in acute lymphoblastic leukemia (ALL) patients. Stopping itraconazole led to symptom resolution in this case and most previously reported cases.
Area of Science:
- Oncology
- Pharmacology
- Toxicology
Background:
- Acute lymphoblastic leukemia (ALL) treatment involves vincristine, a chemotherapy agent.
- Vincristine can cause neurotoxicity, a significant side effect.
- Itraconazole is an antifungal medication with potential drug interactions.
Observation:
- A pediatric patient with ALL developed severe neurotoxicity during concurrent treatment with vincristine and itraconazole.
- This event mirrors previously documented cases of itraconazole-enhanced vincristine toxicity in ALL patients.
Findings:
- The patient's neurotoxicity symptoms resolved completely after itraconazole was discontinued.
- Out of 11 reported cases, including this one, 10 patients experienced complete symptom resolution upon itraconazole cessation.
Implications:
- Clinicians should be vigilant about the potential for severe drug interactions between itraconazole and vincristine.
- Monitoring for neurotoxicity is crucial in ALL patients receiving both medications.
- This highlights the importance of drug interaction awareness in pediatric oncology to prevent life-threatening adverse events.
Abstract:
A boy with acute lymphoblastic leukemia (ALL) experienced life-threatening vincristine neurotoxicity while simultaneously exposed to itraconazole. Five pediatric and six adult cases of itraconazole-enhanced vincristine toxicity have been reported, all with ALL. Upon cessation of the itraconazole, the patient's symptoms resolved, which is similar to the outcome of the previously reported cases: 10 of 11 patients had complete resolution of symptoms.